Τόμος 4 (1990) – Τεύχος 2 – Άρθρο 2 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 4 (1990) – Issue 2 – Article 2 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Laboratory of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, University of Patras, Patra, Greece

Accepted for publication: October 29, 1989

pharmakonpress[at]pharmakonpress[.]gr

2.       Fex, H.J., Hogberg, K.B., Konyves, Κ.: Corticosteroid p-bis (2-chloroethyl) aminophenylcarboxylates as antitumor agents. Ger. Offert. 2,001, 305 (1970). Chem. Abstr. 73: 99119n (1970)

3.       Evertaar, A.H., Wins, E.H.R., van Putten, L.M.: Cell killing effectiveness of an alkylating steroid (Leo 1031). Eur. J. Cancer 9: 773 (1973)

4.       Brandt, L., Konyves, I., Möller, T.R.: Therapeutic effect of Leo 1031, an alkylating corticosteroid ester in lympho-proliferative disorders. Acta Med. Scand. 197: 317 (1975)

5.       Möller, T.R., Brandt, L., Könyves, I., Lindberg, L.G.: Therapeutic effect of Leo 1031 an alkylating corticosteroid ester. Lymphoproliferative Disorders 197: 323 (1975)

6.       Konyves, L., Nordenskjoid, B., plym Forshell, G., De Schryver, A., Westerberg-Larsson, H.: Preliminary clinical and absorption studies with prednimustine in patients with mammary carcinoma. Eur. J. Cancer 11: 841 (1975)

7.       Kaufman, J.H., Hanjura, G.L., Mittelman, A., Aungst, C.W., Murphy. G.P.: Study of Leo 1031 (NSC-134087) in lymphocytic lymphoma and chronic lymphocytic leukemia. Cancer Treat. Rep. 60: 277 (1976)

8.       Brandt, L, Konyves, Κ.: Therapeutic effect of prednimustine (Leo 1031) in various types of leukemia. Eur. J. Cancer 13: 393 (1977)

9.       Harrap, K.R., Riches, P.G., Gilby, E.D., Sellwood, S.M., Wilkinson, R., Könyves, I.: Studies on the toxicity and antitumor activity of prednimustine, a prednisolone ester of chlorambucil. Eur. J. Cancer 13: 873 (1977)

10.     Fredholm, B., Gunmarsson, Κ., Jensen, G., Muntzing, J.: Mammary tumor inhibition and subacute toxicity in rats of prednimustine and of its molecular components chlorambucil and prednimustine. Acta Pharmacol. Toxicol. 42. 159 (1978)

11.     Hakanson, L., Könyves, I., Lindberg, L.G., Möller, T.: Continuous treatment of non-Hodgkin’s malignant lymphoma with prednimustine (Leo 1031). Oncology 53: 103 (1978)

12.     Newell, D.R., Shephered, C.R., Harrap, K.R.: The pharmacokinetics of prednimustine and chlorambucil in the rat. Cancer Chemother. Pharmacol. 6: 85 (1981)

13.     Kirdani, R.Y., Murphy, G.P., Sandberg; A.A.: Some metabolic aspects of a nitrogen mustard of prednisolone. Oncology 35: 47 (1978)

14.     Sayed, A., VanHove, W., Vermeulen, A.: Prednisolone plasma levels after oral administration of prednimustine. Oncology 38: 351 (1981)

15.     Jakhammer, T., Olsson, A., Svensson, L: Mass frag- mentographic determination of prednimustine and chlorambucil in plasma. Acta Pharm. Suec. 14: 485 (1977)

16.     Newell, D.R., Hart, L.I., Harrap, K.R.: Estimation of chlorambucil, phenylacetic mustard and prednimustine in human plasma by high-performance liquid chromatography. J. Chromatography 164: 114 (1979)

17.     Hogberg, K.B., Fex, H.J., Konyves, I., Kneip, H.O.J.: Steroid esters. German Patent. 1, 249, 862 (1967)

18.     Group European du Cancer du Sein. Essai clinique du phenol bis bis (2-chloroethyl)carbamate d’oestradiol dans te cancer mammaire en phase avancée. Eur. J. Cancer 58: 1 (1969)

19.     Yamanaka, H., Shimazaki, J., Imai, Κ., Sugiyama, Y., Shida, Κ.: Effect of estracyt on the rat prostate. Invest. Urol. 14: 400 (1977)

20.     Von Hoff, D.D., Rozencweig, M., Slavik, M., Muggia, F.M.: Estramustine phosphate a specific chemotherapeutic agent? J. Urol. 117: 464 (1977)

21.     Alfthan, O.S., Rusk, J.: Estracyt in advanced prostatic carcinoma. Ann. Chir. Gynaec. Fenn. 58: 234 (1969)

22.     Lindberg, B.: Treatment of rapidly progressing prostatic carcinoma with Estracyt. J. Urol. 108: 303 (1972)

23.     Szendroi, A., Konyves, I., Szendi, L., Eckhardt, S., Hartay, F.: Int. Urol. Nephrol. 6: 101 (1974)

24.     de Levai, J., Petit, R.. Bouffioux, C.: Résultats préliminaires d’une néoplasie prostatic avancée traitée par estracyt. Acta Urol. Belg. 42: 326 (1974)

25.     Mittelman, A., Shukla, S.Κ., Welvaart, Κ., Murphy, G.P.: Oral estramustine phosphate (NSC 89199) in the treatment of advanced (stage D) carcinoma of the prostate. Cancer Chemother. Rep. 59: 219 (1975)

26.     Mittelman, A., Shukla, S.Κ., Murphy, G.P.: Extended therapy of stage D carcinoma of the prostate with oral estramustine phosphate. J. Urol. 115: 409 (1976)

27.     Fossa, S.D., Miller, A.: Treatment of advanced carcinoma of the prostate with estramustine phosphate. J. Urol. 115: 406 (1976)

28.     Nilsson, T., Jonsson, G.: Clinical results with estramustine phosphate (NSC 89199): a comparison of the intravenous and oral preparations. Cancer Chemother. Rep. : 59: 229 (1975)

29.     Nilsson, T., Jonsson, G.: Primary treatment of prostatic carcinoma with estramustine phosphate: preliminary report. J. Urol. 115: 168 (1976)

30.     Jonsson, G., Hogberg, B.: Treatment of advanced prostatic carcinoma with estracyt. Scand. J. Urol. Nephrol. 5: 103 (1971)

31.     Muntzing, J., Shukla, S.G., Chu, T.M. et al.: Pharmaceutical study of oral estramustine phosphate (Estracyt) in advanced carcinoma of the prostate. Invest. Urol. 12: 65 (1974)

32.     Murphy, G.P.: Prostatic cancer. Progress and perspectives. In: Perspectives in Cancer Research and Treatment (G.P. Murphy, D. Press man and E. Mirand, eds), p. 1, Alan R. Liss, New York, 1975

33.     Nitsson, T., Muntzing, J.: Histochemical and biochemical investigation of advanced prostatic carcinoma treated with estramustine phosphate, Estracyt. Scand J. Urol. Nephrol. 7: 18 (1973)

34.     Mittelman, A., Catane, R., Murphy, G.P.: New steroidal alkylating agents in advanced stage D carcinoma of the prostate. Cancer Treat. Rep. 81: 307 (1977)

35.     Kirdani, R.Y., Muntzing, J., Varkarakis, M.J., Murphy, G.P., Sandberg, A.A.: Studies on the antiprostatic action of estracyt, a nitrogen mustard of estradiol. Cancer Res. 34: 1031 (1974)

36.     Kirdani, R.Y., Mittelman, A., Murphy, G.P., Sandberg, A.A.: Studies on phenolic steroids in human subjects. Fate of a nitrogen mustard of estradiol-17b. J. Clin. Endocr. 41: 305 (1975)

37.     Kirdani, R.Y., Murphy, G.P., Sandberg, A.A.: Studies on a nitrogen mustard of estradiol in dogs and rats. Proc. Soc. Exp. Biol. Med 155: 94 (1977)

38.     Tritsch, G.L., Shukla, S.K., Mittelman, A., Murphy, G.P.: Estracyt as a substrate for phosphatases in human serum. Invest. Urol. 12: 38 (1974)

39.     Cavana, M., Brambilla, G., Maura, A., Finollo, R.: Immunodepressive activity of estracyt in mice. IRCS Med. Sci. Libr. Compend. 3: 19 (1975)

40.     Hoeisaeter, Per A.: Incorporation of H-thymidine and carbon-14-labeled amino acids into the ventral prostate after in vivo treatment with estradiol-3N-bis (2-chloro-ethyl) carbamate-17b-phosphate (estracyt) and its estrogen and cytostatic parts. Invest. Urol., 14: 85 (1976)

41.     Leclercq, G., Heuson, J.-C., Deboel, M.C.: Estrogen receptors interaction with Estracyt and degradation products, a biochemical study on a potential agent in the treatment of breast cancer. Eur. J. Durg. Metab. Phar- macokin. 2: 77 (1976)

42.     Plym Forshell, G.O., Munting, J.Ek.A., Lindstedt, E., Dencker, H.: The absorption, metabolism and excretion of estracyt in patients with prostatic cancer. Invest. Urol. 14: 128 (1976)

43.     McMillin, J.M., Seal, U.S.: Effect of oral estramustine phosphate on pituitary gonadal adrenal function in the green monkey. Invest. Urol. 15: 151 (1977)

44.     Kadohama, N., Kirdani, R.Y., Murphy, G.R., Sandberg, A.A.: Estramustine phosphate: Metabolic aspects related to its action in prostatic cancer. J. Urol. 119: 235 (1978)

46.     Forsgren, B„ Crunnarsson, P.O., Johansson, S.A., Kant, R.: Radioimmunoassay of estramustine phosphate in plasma. Acta Pharm. Suec. 15: 200 (1978)

47.     Muntzing, J., Jensen, G. and Hodberg, B.: Pilot study on the growth inhibition by estramustine phosphate (estracyt) of rat mammary tumors sensitive and insensitive to estrogen. Acta Pharmacol. Toxicol. 44: 1 (1979)

48.     Muechler, E.K., Kohler, D.: Interaction of the cytotoxic agent estramustine phosphate (estracyt) with the estrogen receptor of the human uterus. Gynecology Oncol. 8: 330 (1979)

49.     Alison, M.R., Wright, N.A.: Effects of estramustine phosphate upon testosterone-induced cell proliferation in accessory sex glands of mice. J. Endocrinol. 83: 339 (1979)

50.     Asai, M., Takeuchi, H., Okada, H.: In vivo interaction between steroidal alkylating agents and oestrogen receptors in rabbit uteri. Acta  Endocrinologica 87: 173 (1978)

51.     Dixon, R., Brooks, M., Gill, G.: Estramustine phosphate: plasma concentrations of its metabolites following oral administration to man, rat and dog. Res. Commun. Chem. Pathol. Pharmacol. 27: 17 (1980)

52.     Brooks, M., Dixon, R.: Determination of estramustine and its 17-keto metabolite in plasma by high-performance liquid chromatography. J. Chromatography 182: 387 (1980)

53.     Forsgren, B., Hogberg, B.: Binding of a nitrogen mustard derivative of estradiol to rat ventral prostate gland and cytosol. In Vermeulen A., Klopper, A., Sciarra, F., Jungblut, P. of the International Study Group for Steroid Hormones, Rome 3-6 Dec. 1975. Amsterdam. North-Holland Publishing Co., p. 431 (1977)

54.     Forsgren, B., Hogberg, H., Gustafsson, J.-A., Pousette, A.: Binding of estramustine, a nitrogen mustard derivative of estradiol-17, in cytosol from rat ventral prostate. Acta Pharm. Suec. 15: 23 (1978)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr